Overview

NovoLog® (insulin aspart) is a rapid-acting human insulin analog sold by Novo Nordisk. NovoLog starts to work almost immediately, compared to Regular insulin which requires about 30 minutes to begin to work. Thus NovoLog can be injected right before a meal, or even immediately after a meal. For parents of children with diabetes who are picky or unpredictable eaters, NovoLog might be just the tool to help match the insulin given to the food eaten.

In addition to working faster, NovoLog has a shorter duration of action than Regular insulin. This means that people who use NovoLog might experience fewer night-time low blood sugars, and need to eat less for their mid-morning and mid-afternoon snacks. It also means that people who use NovoLog might need to increase their long-acting insulin (NPH or Ultralente for example) a little to compensate for the absence of the trailing action of Regular insulin.

NovoLog is taken in the same amount as Regular insulin. It can be mixed with NPH, but has not been tested with crystalline zinc insulins such as Lente and Ultralente and therefore should not be mixed with them. NovoLog is available in 10ml vial and 3ml cartidges. Like other insulin analogs, a prescription is needed for NovoLog in the US. Outside the United States, NovoLog is sold as NovoRapid®.

For More Information

• Longer Infusion Site Lifetime with NovoLog Reported
• FDA Approves NovoLog® Category Change for Use in Pregnant Women with Type 1 Diabetes.
• Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes.
• Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion.
• Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes
• FDA Medical Reviewer Report in Insulin Aspart and Its Use in a Pump
• Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes
• Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin
• Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial
• NovoLog Prescribing Information

Posted September 30, 2001
Updated February 11, 2007

Last Updated: Sun Feb 11 13:08:44 2007
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by Children With Diabetes, Inc, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice and Privacy Policy.
© Children with Diabetes, Inc. 1995-2008. Comments and Feedback.